The ALS Therapy Development Institute (ALS TDI) announced today that it will establish a national partnership with It’s Just Lunch, a specialized dating service for busy single professionals, to raise funds and awareness of ALS. Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a progressive and fatal neurodegenerative disease that affects 30,000 Americans each year.
“We are pleased to have the support of It’s Just Lunch and its members,” said Sean Scott, president of ALS TDI. “This partnership will provide critical funding for research into a treatment for ALS. The generosity It’s Just Lunch has shown already and the continued support of its membership will help to speed that research and will provide hope to tens of thousands of ALS patients all over the world.”
This partnership will begin Saturday, Dec. 1 with a special membership and donation opportunity and will continue with regional events throughout 2008. During the month of December, participating It’s Just Lunch offices will take $100 off any membership program for each new member that joins. Its Just Lunch will also donate $100 for each new membership in December to ALS TDI to fund research.
“As an It’s Just Lunch franchise owner, I am very please to be spearheading our partnership with ALS TDI” said Paula Komar, owner of It's Just Lunch in the Detroit Suburbs. “We and the entire It’s Just Lunch family hope that our efforts, along with the efforts of those involved with ALS TDI, will help find a cure for this disease that affects so many.”
The ALS Therapy Development Institute (ALS TDI), based in Cambridge, Mass., was founded in 1999 as the ALS Therapy Development Foundation. Today an institutional leader in ALS research, ALS TDI operates the world’s largest research and development program focused exclusively on ALS. A staff of more than 25 scientists and technicians work on behalf of ALS patients to discover and advance the best new ideas for stopping ALS. It excels in identifying novel disease targets, discovering compounds that may act against these targets and screening these potential treatments towards bringing viable therapeutics to the clinic. For more information, visit www.als.net.